FGFR4 and cancer: A meta and pooled analyses provide evidence of a role for the FGFR4 Gly388Arg polymorphism in modulating patients’ outcome in different types of cancer, thus offering to clinicians a new marker to predict predisposition to poor survival in cancer patients [29].